Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥15.460B | ¥14.818B | +4.3% |
| Operating Income | ¥0.064B | ¥0.081B | −20.2% |
| Equity-Method Investment Gain/Loss | - | - | - |
| Ordinary Income | ¥0.084B | ¥0.101B | −16.2% |
| Net Income | ¥0.038B | ¥0.072B | −46.9% |
| ROE | 0.3% | 0.6% | - |
Executive Summary
Although the Company secured revenue growth, both Operating Income and Net Income fell below the previous year due to increases in selling, general and administrative expenses and the tax burden, resulting in higher revenue but lower earnings. Revenue was ¥15.460B (+4.3% year on year), Operating Income was ¥0.064B (-20.2%), Ordinary Income was ¥0.084B (-16.2%), and Net Income attributable to owners of the parent was ¥0.036B (-48.2%). The gross profit margin improved by +0.1pt to 8.0%, but the SG&A ratio deteriorated by +0.2pt to 7.6%, resulting in lower Operating Income. In addition, the effective tax rate was high at 58.8%, which widened the decline in Net Income.
Factors Driving Earnings Fluctuations
【Revenue】Revenue increased 4.3% year on year to ¥15.460B. The core Pharmaceutical Wholesale Business led overall performance, with revenue of ¥14.780B (+4.3%), maintaining its growth trend as the central business, accounting for 93.8% of sales to external customers. The Nursing Care Rental and Other Business posted strong growth of 19.5% to ¥0.237B, while the Veterinary Pharmaceutical Wholesale Business was largely flat at ¥0.308B (-0.3%).
【Profit and Loss】Operating Income declined 20.2% year on year to ¥0.064B, as the ¥0.082B increase in SG&A expenses exceeded the ¥0.066B increase in gross profit. The Operating Income margin declined to 0.4% from 0.5% in the previous year, as the +0.1pt improvement in the gross profit margin was offset by the +0.2pt increase in the SG&A ratio. Ordinary Income was ¥0.084B (-16.2%); although non-operating income of ¥0.027B, including ¥0.012B in dividend income, provided support, it was insufficient to offset the decline in Operating Income. Extraordinary income of ¥0.008B, comprising a ¥0.004B gain on the sale of investment securities and a ¥0.004B gain on the sale of fixed assets, was recorded as a temporary factor, but declined from ¥0.030B in the previous year, limiting its contribution to Net Income. Against Profit Before Tax of ¥0.093B, income taxes and other taxes of ¥0.054B were recorded, resulting in a high effective tax rate of 58.8%. Consequently, Net Income attributable to owners of the parent declined 48.2% year on year to ¥0.036B, a sharper decline than Ordinary Income. Despite revenue growth, higher expenses and an increased tax burden pressured earnings, resulting in higher revenue but lower earnings.
Segment Analysis
The core Pharmaceutical Wholesale Business remained solid in both scale and profitability, with revenue of ¥14.780B (+4.3%), Operating Income of ¥0.110B (+1.9%), and a profit margin of 0.7%, supporting the majority of Company-wide Operating Income. In contrast, the Pharmacy Business recorded revenue of ¥0.490B (+1.1%), but its operating result fell to a loss of ¥0.006B from a profit in the previous year, resulting in a profit margin of -1.2%. The Veterinary Pharmaceutical Wholesale Business generated revenue of ¥0.308B (-0.3%) and Operating Income of ¥0.007B (-5.2%), but its profit margin of 2.4% was the highest among all segments. The Pharmaceutical Business recorded an operating loss of ¥0.042B, which expanded further from the previous year's loss (-37.3%), while the Nursing Care Rental and Other Business increased revenue 19.5% to ¥0.237B but remained at an operating loss of ¥0.006B. In addition to the low-margin structure of the core business, losses in the three non-core segments are diluting the Company-wide profit margin.
Key Financial Indicators
【Profitability】The Operating Income margin was 0.4%, slightly below 0.5% in the previous year. Although the gross profit margin improved to 8.0% from 7.9%, the SG&A ratio increased to 7.6% from 7.4%, offsetting the improvement. The Net Income margin, based on income attributable to owners of the parent, was 0.2%, down from 0.5% in the previous year.【Cash Quality】Cash and deposits totaled ¥2.276B, while interest-bearing debt, comprising the total of short-term borrowings, current portion of long-term borrowings, and long-term borrowings, was approximately ¥0.460B, securing net cash of approximately ¥1.817B. Accounts receivable increased 5.1% year on year, while inventories decreased 6.1%, indicating a change in the composition of working capital.【Investment Efficiency】ROE was 0.3% based on quarterly results, and the Equity Ratio was 35.5%, down from 36.6% in the previous year. Total assets were ¥32.228B, remaining almost flat year on year, while net assets were ¥11.592B, down from ¥11.871B in the previous year.【Financial Soundness】Current assets of ¥19.757B compared with current liabilities of ¥18.832B resulted in a current ratio of 104.9%. Non-current liabilities were ¥1.805B, relatively small compared with current liabilities, and the liability structure was centered on short-term trade payables, including accounts payable of ¥17.406B.
Cash Flow Analysis
As the Company does not disclose a cash flow statement, cash trends are assessed based on changes in the balance sheet. Cash and deposits were ¥2.276B, remaining almost flat from ¥2.295B in the previous year. In terms of working capital, accounts receivable and notes receivable increased 5.1% year on year, while inventories decreased 6.1% and accounts payable and notes payable increased 2.5%. Interest-bearing debt, comprising short- and long-term debt, was approximately ¥0.460B, a slight decrease from approximately ¥0.483B in the previous year. After deducting this from cash and deposits, the Company maintained net cash of approximately ¥1.817B. As the increase in accounts receivable exceeded the reduction in inventories, funds appear to have become somewhat tied up in working capital, particularly trade receivables, and the timing of cash conversion may be affecting capital efficiency.
Quality of Earnings
Recurring earnings are centered on the core commercial trading business. Non-operating income of ¥0.027B comprised stable items such as dividend income of ¥0.012B and interest income of ¥0.001B, and was limited in scale at approximately 0.2% of revenue. As a temporary factor, the Company recorded extraordinary income of ¥0.008B, consisting of a ¥0.004B gain on the sale of investment securities and a ¥0.004B gain on the sale of fixed assets. However, this declined from ¥0.030B in the previous year, and its contribution to earnings was limited. Against Ordinary Income of ¥0.084B, Net Income attributable to owners of the parent was ¥0.036B. This gap was attributable to income taxes and other taxes of ¥0.054B against Profit Before Tax of ¥0.093B and the high effective tax rate of 58.8%. The significant divergence between earnings at the Ordinary Income stage and final Net Income is an important consideration when evaluating earnings quality. The change in asset composition, namely the increase in accounts receivable and decrease in inventories, also provides a basis for assessing the pace of cash conversion from an accrual perspective.
Earnings Forecasts and Guidance
Progress against the Full-Year plan was approximately in line with normal levels for Revenue at 24.9% (¥15.460B/¥62.000B). However, progress was slower for Operating Income at 15.7% (¥0.064B/¥0.410B), Ordinary Income at 16.9% (¥0.084B/¥0.500B), and Net Income attributable to owners of the parent at 4.8% (¥0.036B/¥0.750B). No revisions were made to either the earnings forecast or the dividend forecast, both of which were stated as “None.” The Company is maintaining its plan based on cost control and improvements in loss-making segments in the second half, as well as normalization of the tax burden. The Full-Year Ordinary Income forecast calls for a substantial 36.1% year-on-year decline, representing a conservative outlook consistent with progress during the first half.
Shareholder Returns
The annual dividend forecast is ¥70.00, with no revision made during the current quarter. Based on the number of shares outstanding of 51,903 thousand shares less treasury shares of 3,864 thousand shares, total annual dividends are estimated at approximately ¥0.336B, implying a Payout Ratio of approximately 45% against the Full-Year Net Income forecast of ¥0.750B attributable to owners of the parent. Treasury shares increased to ¥0.448B from ¥0.396B in the previous year, confirming progress in share repurchases. The Payout Ratio based solely on dividends is approximately 45%. Considering the cash and deposits balance of ¥2.276B and the net cash position of approximately ¥1.817B, the Company appears to have a certain degree of flexibility in funding dividends.
Risk Factors
-
Concentration risk in the business portfolio: The Pharmaceutical Wholesale Business accounts for 93.8% of sales to external customers (¥14.780B/¥15.460B), creating a structure in which supply-demand and pricing trends in this business have a significant impact on Company-wide performance.
-
Low-margin structure and continued losses in non-core businesses: The Company-wide Operating Income margin is low at 0.4%, while the Pharmacy Business (operating loss of ¥0.006B), Pharmaceutical Business (loss of ¥0.042B), and Nursing Care Rental and Other Business (loss of ¥0.006B) all reported losses, diluting profits from the core business.
-
Risks related to the tax burden and working capital: The effective tax rate for Q1 was high at 58.8%, amplifying fluctuations in Net Income. In addition, accounts receivable increased 5.1% year on year while inventories decreased 6.1%, and changes in the asset composition may affect the timing of cash conversion.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (trading)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 0.4% | 4.3% (1.7%–6.9%) | −3.9pt |
| Net Income Margin | 0.2% | 3.8% (1.5%–5.1%) | −3.5pt |
Both the Company's Operating Income margin and Net Income margin are significantly below the industry median, placing the Company in the low-profitability group within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year on Year) | 4.3% | 3.1% (-0.6%–11.7%) | +1.2pt |
The Revenue growth rate exceeds the industry median, indicating that the pace of revenue growth is relatively high within the industry.
Source: Compiled by the Company
Key Takeaways from the Earnings Results
-
Despite revenue growth, the increase in the SG&A ratio (+0.2pt) reduced the Operating Income margin to 0.4%. The increase in expenses offset the improvement in the gross profit margin (+0.1pt), determining the Company's profitability during the current period.
-
The high effective tax rate of 58.8% widened the decline in Net Income attributable to owners of the parent (-48.2%) compared with Ordinary Income (-16.2%). Progress toward the Full-Year plan was also slower at the Net Income level, with progress of only 4.8%, than at the Revenue and Ordinary Income levels.
-
While the core Pharmaceutical Wholesale Business maintained higher revenue and higher earnings, the Pharmacy, Pharmaceutical, and Nursing Care Rental and Other businesses each recorded operating losses. Improving the profitability of the non-core businesses will be a key issue in restoring the Company-wide profit margin.
Theoretical Share Price (Reference Value)
This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥1,963 |
| base | ¥1,969 |
| bull | ¥1,980 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥2,413 |
| Adjusted Forecast EPS | ¥69.8 |
| Cost of Equity r | 9.77% (10-year government bond 2.77% + equity risk premium 6.00% + size premium 1.00%) |
| Persistence Coefficient of Residual Income ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 45.1% |
| Forecast EPS Confidence Adjustment | ×1.037 (based on the industry's historical guidance achievement rate) |
| implied PBR / PER | 0.82x / 28.2x |
Sensitivity: ¥1,916–¥2,025 at ±1% for the cost of equity, and ¥1,955–¥1,978 at ±0.1 for ω.
Notes:
- Normalized EPS calculated from Ordinary Income and other figures is used to exclude the impact of temporary profit and loss items (the Company's forecast EPS is ¥155.0).
- As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the end of the quarter are used; there is a timing gap with the Full-Year forecast.
- As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.
(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee future share prices)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2027 Q1 was a mixed quarter: sales growth remained positive, but profitability and earnings conversion weakened materially. Revenue increased 4.3% year on year to ¥154.60bn. Gross profit rose 5.6% to ¥12.41bn, marginally outpacing revenue growth. Consequently, gross margin improved by approximately 10bp year on year to 8.0%. However, SG&A expenses increased 7.5% to ¥11.77bn, faster than revenue. The SG&A-to-sales ratio therefore increased by approximately 22bp to 7.6%. Operating income declined 20.2% to ¥0.643bn. Operating margin compressed by approximately 13bp to 0.4%, underscoring the structurally thin margin profile of pharmaceutical wholesaling. Ordinary income fell 16.2% to ¥0.843bn. Profit attributable to owners of parent dropped 48.2% to ¥0.359bn, producing EPS of ¥7.44. The decline in net income was amplified by a 58.8% effective tax rate, compared with a tax burden of 38.8% of profit before tax. Profit before tax included ¥0.83bn of extraordinary gains, comprising ¥0.44bn from securities sales and ¥0.39bn from asset sales. Dividend income of ¥1.25bn also remained a meaningful support to ordinary income, exceeding operating income. Comprehensive income was negative ¥0.52bn despite positive net income, principally reflecting a ¥7.15bn negative valuation difference on securities within other comprehensive income. The core pharmaceutical wholesale segment grew sales and modestly increased segment profit, but this was insufficient to offset deteriorating profitability in pharmacy and pharmaceutical operations. Q1 sales progress against the full-year forecast was broadly normal at 24.9%, while operating-income progress was only 15.7%. The earnings outlook therefore depends on a substantial improvement in operating profitability after Q1, particularly through the remainder of the pharmaceutical wholesale cycle and loss reduction in unprofitable businesses.
Profitability Analysis
Annualized DuPont ROE was 1.2%, comprising a 0.2% net profit margin, 1.919x asset turnover, and 2.78x financial leverage. The dominant constraint on shareholder returns is the extremely low net margin rather than asset utilization. Asset turnover is relatively high on an annualized basis, which is consistent with a high-volume distribution model, but the benefit is largely absorbed by the narrow spread between gross profit and operating costs. Financial leverage supports reported ROE mechanically, although the balance sheet is not reliant on large interest-bearing borrowings. Gross margin improved to 8.0% from approximately 7.9% in the prior-year quarter, indicating that gross-profit generation kept pace with sales growth. The more consequential change was operating leverage: SG&A rose 7.5%, versus 4.3% revenue growth, driving operating-income contraction. EBIT margin of 0.4% is a material low-operating-efficiency alert, as limited pricing or cost variation can have an outsized effect on earnings. The effective tax rate of 58.8% is also a material burden, reducing the conversion of ¥0.925bn profit before tax into ¥0.359bn profit attributable to owners. Interest coverage remained strong at 35.72x, so interest costs are not the cause of weak profitability. Annualized ROIC of 1.3% is below the 5% warning threshold, indicating that current operating returns do not adequately compensate for the capital employed in receivables, inventory, fixed assets, and investments. The low 8.0% gross margin is characteristic of wholesale distribution economics, but it leaves limited capacity to absorb SG&A inflation. The modest gross-margin improvement is constructive, yet sustained recovery requires SG&A discipline and better profitability in loss-making operations rather than volume growth alone.
Growth Assessment
Revenue growth was led by the core pharmaceutical wholesale business, where external sales increased 4.3% year on year to ¥144.98bn and segment profit increased 1.9% to ¥1.103bn. This segment accounted for the overwhelming majority of consolidated sales and the largest operating-income contribution, making it the core business. Its segment margin eased slightly to approximately 0.7% from 0.8%, indicating that incremental sales did not fully translate into higher profitability. Pharmacy external sales increased 1.1% to ¥4.89bn, but segment performance deteriorated to a ¥0.60bn loss from a ¥0.42bn profit. Animal pharmaceutical wholesale sales declined 0.3% to ¥3.08bn and segment profit decreased 5.2% to ¥0.73bn. The pharmaceutical business remained loss-making, with its segment loss expanding to ¥4.20bn from ¥3.06bn. Care rental and other businesses delivered the strongest sales growth, with external revenue rising 27.7% to ¥1.65bn, while the segment loss narrowed to ¥0.61bn from ¥0.85bn. The full-year plan calls for sales of ¥620.0bn, up 1.6%, and Q1 progress of 24.9% is close to the standard 25% quarterly pace. Full-year operating income is forecast at ¥4.10bn, up 1.8%, but Q1 progress of 15.7% is 9.3 percentage points below the standard pace. Ordinary-income progress was 16.9% against the ¥5.00bn forecast, also below a normal Q1 run rate. Profit attributable to owners progressed only 4.8% against the ¥7.50bn forecast, reflecting the weak Q1 tax outcome and the need for significant earnings concentration in later quarters. Management has not revised its earnings or dividend forecasts. The forecast is achievable only if the core wholesale operation preserves gross-profit gains, SG&A growth moderates, and losses in pharmacy and pharmaceutical businesses are contained.
Financial Health
Liquidity is adequate but tight for a distribution business, with a current ratio of 104.9% and working capital of ¥9.25bn. The quick ratio of 88.3% is below 1.0x, so the group depends partly on inventory liquidation and regular receivables collection to meet current obligations. Current liabilities of ¥188.32bn are predominantly supported by current assets of ¥197.57bn, while trade payables of ¥174.06bn are the principal liability item. Trade receivables were ¥127.43bn, inventories ¥31.24bn, and cash and deposits ¥22.76bn. Interest-bearing debt was modest at ¥4.60bn, equivalent to approximately 4.0% of total equity, and debt/capital was only 3.8%. The reported D/E ratio of 1.78x primarily reflects the liability-heavy working-capital structure inherent in wholesale operations rather than financial debt dependence. Short-term loans were ¥0.95bn, while cash was 24.0x short-term debt, limiting refinancing and immediate maturity-mismatch risk. Interest coverage of 35.72x further indicates ample capacity to service borrowing costs. Equity declined ¥2.79bn year on year to ¥115.92bn, largely reflecting negative other comprehensive income rather than the quarter's income statement alone. The capital adequacy ratio declined to 35.5% from 36.6%, but remains supported by ¥85.45bn of shareholders' equity and ¥28.97bn of accumulated other comprehensive income. Goodwill was only ¥2.56bn, or 2.2% of equity and 0.8% of assets, leaving balance-sheet valuation risk from acquired goodwill limited. Investment securities of ¥52.01bn, or 16.1% of assets, remain a meaningful source of equity-market sensitivity.
Notable B/S Changes
Trade receivables: +¥6.19bn year on year to ¥127.43bn - receivables remain 39.5% of assets and contribute to elevated annualized DSO of approximately 75 days, making collection efficiency a key cash-conversion variable. Provision for bonuses: +¥9.05bn (+57.3%) year on year to ¥24.84bn - the increase raises current-liability requirements and may reflect seasonal personnel-cost accruals. Total equity: -¥2.79bn (-2.4%) year on year to ¥115.92bn - negative securities valuation movements reduced comprehensive income and modestly lowered the capital adequacy ratio to 35.5%.
Cash Flow Quality
The balance-sheet cash conversion profile requires close monitoring because receivables are large relative to the operating margin. Annualized days sales outstanding were approximately 75 days, above the 60-day alert threshold. This high receivable-days alert reflects substantial capital tied up in customer credit and exposes operating cash generation to payment timing and collection performance. Trade receivables increased ¥6.19bn year on year, broadly in line with the revenue increase but still representing 39.5% of total assets. Inventories declined ¥2.04bn year on year to ¥31.24bn, which is favorable for working-capital discipline and partly offsets the receivables increase. Accounts payable increased ¥4.30bn to ¥174.06bn, maintaining supplier-financed working capital typical of the wholesale model. Cash and deposits were broadly stable at ¥22.76bn. The combination of a 0.4% EBIT margin and 75-day receivables means that even modest delays in collections could materially affect liquidity and earnings conversion. Extraordinary gains of ¥0.83bn exceeded reported net income attributable to owners of ¥0.359bn, so underlying cash-generative operating performance should be assessed separately from asset and securities disposal gains. Negative comprehensive income of ¥0.52bn also demonstrates that securities valuation movements can reduce equity even when reported net income is positive.
Dividend Sustainability
The company forecasts a full-year dividend of ¥70.00 per share and full-year EPS of ¥155.03. The implied forecast dividend payout ratio is approximately 45.2%, which is below the 60% sustainability benchmark. This policy appears supportable relative to the full-year earnings target if that target is achieved. The Q1 EPS of ¥7.44 is not representative of the full-year distribution capacity because quarterly earnings were weighed down by the elevated tax rate and weak operating-income progress. Retained earnings remained substantial at ¥796.27bn, providing a meaningful accounting buffer for shareholder distributions. The principal consideration for dividend sustainability is therefore not leverage, given modest interest-bearing debt, but restoration of operating earnings and cash conversion from receivables. No dividend forecast revision has been announced.
Risk Assessment
Business risks include Pharmaceutical wholesale pricing and reimbursement pressure: the core business generated approximately ¥144.98bn of Q1 external sales but only a roughly 0.7% segment margin, leaving earnings highly sensitive to small changes in pricing, purchase conditions, and distribution costs., Loss-making business exposure: the pharmacy segment shifted to a ¥0.60bn loss and the pharmaceutical segment loss widened to ¥4.20bn; continued deterioration would dilute the otherwise stable core wholesale business., Receivable collection risk: annualized DSO of approximately 75 days exceeds the 60-day alert threshold, increasing working-capital intensity and sensitivity to customer payment behavior., Investment-market risk: investment securities total ¥52.01bn and valuation differences on securities produced a ¥7.15bn negative OCI movement during Q1, demonstrating material equity sensitivity to market prices., Healthcare-sector cost inflation: labor, logistics, and compliance costs can rise faster than the group’s ability to pass costs through in low-margin pharmaceutical distribution..
Financial risks include Low operating efficiency: the 0.4% EBIT margin is below the 5% alert threshold, meaning limited earnings resilience against cost inflation, pricing changes, or adverse mix shifts., Low capital efficiency: annualized ROIC of 1.3% is below the 5% warning level, indicating weak returns on the capital tied up in distribution assets and investments., High tax burden: the 58.8% effective tax rate and 0.388 tax-burden factor materially reduced net-income conversion in Q1., Tight short-term liquidity profile: the 104.9% current ratio is above 1.0x but the 88.3% quick ratio is below 1.0x, making efficient collections and supplier-payment management important., Earnings dependence on non-operating and non-recurring items: dividend income was ¥1.25bn and extraordinary gains were ¥0.83bn, while operating income was only ¥0.643bn..
Key concerns include The largest near-term issue is the divergence between 4.3% sales growth and a 20.2% decline in operating income, driven by SG&A growth exceeding revenue growth., The full-year operating-income plan requires a meaningful post-Q1 recovery because Q1 progress was 15.7%, below the standard 25% pace., The 8.0% gross-margin alert is structurally relevant to a wholesaler: although margin improved modestly year on year, the low spread provides little buffer against operating-cost increases., Negative comprehensive income despite positive net income highlights the importance of monitoring securities valuations and the resulting effect on book value and capital adequacy..
Investment Implications
Key takeaways include Core pharmaceutical wholesale sales and segment profit continued to grow, supporting top-line stability., Consolidated profitability weakened because SG&A growth outpaced revenue and non-core operations remained loss-making., The annualized 1.2% ROE and 1.3% ROIC identify profitability, rather than balance-sheet debt, as the key capital-efficiency challenge., Low interest-bearing debt, strong interest coverage, and limited goodwill reduce financing and acquisition-related balance-sheet risk., The full-year forecast embeds a substantial improvement in earnings after Q1, particularly for operating income and profit attributable to owners..
Metrics to watch include Core pharmaceutical wholesale segment margin and consolidated gross margin, SG&A growth relative to revenue growth, Pharmacy and pharmaceutical segment losses, Annualized receivable days and trade-receivable balance, Operating-income and ordinary-income progress against the FY2027 plan, Effective tax rate and the proportion of earnings from dividend income and disposal gains, Valuation differences on investment securities and capital adequacy ratio.
Regarding relative positioning, The group has the balance-sheet characteristics of a conservatively debt-funded, working-capital-intensive healthcare distributor: high asset turnover and strong interest coverage, but very low operating and capital returns. Its limited goodwill exposure compares favorably with acquisitive peers, while its thin margin, high receivable days, and earnings weakness in non-core segments constrain financial flexibility at the operating level.